Pamidronate
Mostrando 1-12 de 27 artigos, teses e dissertações.
-
1. Cyclic pamidronate treatment for osteogenesis imperfecta: Report from a Brazilian reference center
Abstract Treatment of moderate and severe forms of osteogenesis imperfecta (OI) with cyclic pamidronate at the Reference Center for OI Treatment in Southern Brazil was studied. A retrospective cohort study was conducted from 2002 to 2012. Data were obtained during inpatient (drug infusion) and outpatient care. Clinical data, including the presence of blue sc
Genet. Mol. Biol.. Publicado em: 25/04/2019
-
2. Humoral hypercalcemia of pregnancy treated with bisphosphonates
SUMMARY Hypercalcemia can be hazardous during pregnancy, most cases being due to primary hyperparathyroidism. We report a case of hypercalcemia with suppressed PTH levels necessitating treatment with bisphosphonates during pregnancy. A 38-year-old woman at the 26th week gestation was admitted because of symptomatic hypercalcemia. She did not take any medicat
Arch. Endocrinol. Metab.. Publicado em: 2018-02
-
3. Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment
OBJECTIVES: The present study was designed to evaluate the bone phenotypes and mechanisms involved in bone disorders associated with hepatic osteodystrophy. Hepatocellular disease was induced by carbon tetrachloride (CCl4). In addition, the effects of disodium pamidronate on bone tissue were evaluated. METHODS: The study included 4 groups of 15 mice: a) C
Clinics. Publicado em: 2017-04
-
4. Mycobacterium avium-intracellulare and the unpredictable course of hypercalcemia in an AIDS patient
Abstract A 37-year-old man with AIDS presented with altered mental status four weeks after stopping his medications for Mycobacterium avium-intracellulare (MAI). He had low CD4 cell count and severe hypercalcemia. Bone marrow biopsy revealed bone marrow infiltration by granulomas positive for acid-fast bacilli and cultures grew MAI. His hypercalcemia continu
Braz J Infect Dis. Publicado em: 2017-02
-
5. Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats
Osteoporosis is a major complication of chronic cholestatic liver disease (CCLD). We evaluated the efficacy of using disodium pamidronate (1.0 mg/kg body weight) for the prevention (Pr) or treatment (Tr) of cholestasis-induced osteoporosis in male Wistar rats: sham-operated (Sham = 12); bile duct-ligated (Bi = 15); bile duct-ligated animals previously treate
Braz J Med Biol Res. Publicado em: 2012-12
-
6. Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
Os glicocorticoides (GC) são prescritos por praticamente todas as especialidades médicas, e cerca de 0,5% da população geral do Reino Unido utiliza esses medicamentos. Com o aumento da sobrevida dos pacientes com doenças reumatológicas, a morbidade secundária ao uso dessa medicação representa um aspecto importante que deve ser considerado no manejo
Revista Brasileira de Reumatologia. Publicado em: 2012-08
-
7. Avaliação da resposta à teriparida em pacientes portadores de osteoporose pseudoglioma. / Evaluation of response to teriparida in patients with osteoporosis pseudogliom.
INTRODUCTION: Osteoporosis Pseudoglioma (OPPG) is characterized by severe juvenile-onset osteoporosis and ocular abnormalities. It is caused by one of several inactivating mutations in LRP5, a gene importantly involved in bone formation. OBJECTIVE: The objective of this study was to evaluate the efficacy of teriparatide in a young man with OPPG. PATIENT AND
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 24/11/2011
-
8. Índices radiomorfométricos de mandíbula e densidade mineral óssea em crianças saudáveis e com diagnóstico de osteogênese imperfeita
Bone mass aquisition in childhood is an important factor in fractures and osteoporosis prevention. Many studies show correlations between bone mineral densities and mandibular radiomorphometric indices in adults. The objective of this research was to verify if such a correlation exists also in growing individuals. Spine and whole-body densitometries and pano
Publicado em: 2009
-
9. Analysis of bisphosphonates using anionic exchange liquid chromatography, ultraviolet indirect detection and by condutivity with eluent supression / Análises de bisfosfonatos por cromatografia líquida de troca aniônica, detecção indireta no ultravioleta e por condutividade com supressão de eluente
This work presents the development of chromatografic methodologies for analysis of Bisphosphonates in drugs, raw material and biological fluids using Ion Chromatography with indirect UV detection and conductivity detection with eluent suppression. In chapter 1, an extensive bibliographical research was accomplished in relationship to the pharmacological prop
Publicado em: 2008
-
10. Treatment of Paget's disease of bone with single dose intravenous pamidronate.
OBJECTIVES--To assess the efficacy of a single intravenous infusion of pamidronate in Paget's disease of bone. METHODS--Fourteen patients with active Paget's disease (raised serum alkaline phosphatase, bone pain or neurological involvement) were treated with a single intravenous infusion of 105 mg pamidronate. Patients were assessed for biochemical and clini
-
11. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta
Cyclical pamidronate infusions increase bone mass in children suffering from osteogenesis imperfecta. The histological basis for these effects remains unknown. Therefore, we compared parameters of iliac bone histomorphometry from 45 patients before and after 2.4 ± 0.6 years of pamidronate treatment (age at the time of the first biopsy, 1.4–17.5 years; 23
American Society for Clinical Investigation.
-
12. Clinical experience with pamidronate in the treatment of Paget's disease of bone.
Bisphosphonates have been shown to be effective in treating the increased bone turnover associated with Paget's disease of bone. In this study two groups of patients were treated with pamidronate by intravenous infusion. In group 1 (n = 15) 30 mg of pamidronate was given once a week for six weeks. A subgroup (group 1A, n = 6) of more severely affected patien